The role of LncRNA LBX2-AS1 in cancers: functions, mechanisms and potential clinical utility

• Yuanshuai Su ^[2] ; Chengzhi Li ^[1] ; Yu Fang ^[2] ; Xinyu Gu ^[2] ; Qiuxian Zheng ^[2] ; Juan Lu ^[2] ; Lanjuan Li ^[2]
  1. [1] Zhejiang University

     Zhejiang University

     China

     
  2. [2] State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, No. 79 Qingchun Road, Shangcheng District, Hangzhou, 310003, Zhejiang, China
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 25, Nº. 2 (February), 2023, págs. 293-305
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Increasingly advanced biology technique has revealed that long non-coding RNAs (lncRNA) as critical factors that exert significant regulatory effects on biological functions by modulating gene transcription, epigenetic modifications and protein translation. A newly emerging lncRNA, ladybird homeobox 2 (LBX2)-antisense RNA 1 (LBX2-AS1), was found to be highly expressed in various tumors. Moreover, it is functionally linked to the regulation of essential tumor-related biological processes, such as cell proliferation and apoptosis, through interactions with multiple signaling molecules/pathways. The important roles played by LBX2-AS1 in cancer initiation and progression suggest that this lncRNA has enormous clinical potential for use as a novel biomarker or therapeutic target. In this article, we retrospectively review the latest advances in research exploring the roles of the lncRNA LBX2-AS1 in oncology field, highlighting its involvement in a comprehensive network of molecular mechanisms underlying diverse cancers and examining its potential applications in clinical practice.